Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Gu, C. et al. FOXM1 is a therapeutic target for high-risk multiple myeloma. Leukemia 30, 873–882 (2016).
2. Nandi, D., Cheema, P. S., Jaiswal, N., Nag, A. FoxM1: repurposing an oncogene as a biomarker. Semin. Cancer Biol. (2017) Pii: S1044-579X(17)30061-5.
3. Hose, D. et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 96, 87–95 (2011).
4. Weinhold, N. et al. Clonal selection and double hit events involving tumor suppressor genes underlie relapse from chemotherapy: myeloma as a model. Blood 128, 1735–1744 (2016).
5. Fry, D. W. et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3, 1427–1438 (2004).
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献